Skip to Content

Bendamustine use while Breastfeeding

Drugs containing Bendamustine: Bendeka, Treanda, Belrapzo

Medically reviewed by Drugs.com. Last updated on April 25, 2021.

Bendamustine Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of bendamustine during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as bendamustine.[1] The manufacturer recommends that breastfeeding be discontinued during bendamustine therapy. Based on the half-life of the drug and its metabolites, the drug should be eliminated from the milk by 24-48 hours after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Some evidence indicates that carmustine can increase serum prolactin.[2]

Substance Identification

Substance Name

Bendamustine

CAS Registry Number

16506-27-7

Drug Class

  • Breast Feeding
  • Lactation
  • Antineoplastic Agents, Alkylating
  • Nitrosourea Compounds

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.